Pluristem Therapeutics (PSTI) resumes trading 14.4% lower after shares were halted following...

|About: Pluristem Therapeutics, Inc. (PSTI)|By:, SA News Editor

Pluristem Therapeutics (PSTI) resumes trading 14.4% lower after shares were halted following news that the FDA has suspended the Phase II trials for the company's placenta-based cell treatment for artery disease.